Skip to content

B-type natriuretic peptide (BNP) testing and monitoring in patients with heart failure (HF) in primary and secondary care in the UK

Effectiveness and cost-effectiveness of serum B-type natriuretic peptide (BNP or NT-BNP) testing and monitoring in patients with heart failure (HF) in primary and secondary care

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN37248047
Enrollment
50000
Registered
2013-08-14
Start date
2013-08-01
Completion date
Unknown
Last updated
2019-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure Circulatory System

Interventions

Exposure: Any BNP measurement (single or multiple). Comparator: No BNP measurement. Patient information is collated from GP practices and hospitals, and linked with ho

Sponsors

University Hospitals Bristol NHS Foundation Trust (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All patients with primary diagnosis of heart failure in CPRD or NHFA, diagnosed between April 2005 and March 2013 (CPRD) and April 2009 and March 2013 (NHFA). HF diagnoses in CPRD will be identified using the Read codes. Code sets will be selected with the help of CPRD researchers and agreed by clinical members of the research team.

Exclusion criteria

Exclusion criteria: Patients who do not meet the inclusion criteria above

Design outcomes

Primary

MeasureTime frame
All-cause mortality within 12 months

Secondary

MeasureTime frame
1. Time from diagnosis of HF (time ?origin? for all time-to-event analyses) to emergency in hospital admission/unscheduled readmission 2. Length of hospital stay 3. Prescribed medications on discharge 4. Time on medication 5. Time to change in medication 6. Annual rate of outpatient clinic and general practice attendance and associated investigations

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 9, 2026